Thursday, February 29, 2024

Ironwood hit after study results

 

  • Ironwood Pharmaceuticals (IRWD) stock is down on Thursday following clinical trial results.
  • The company’s Phase III apraglutide study met its primary endpoint.
  • However, it only met two of its four secondary endpoints.
at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.